首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal TGFBR1 Antibody

  • 中文名: TGFBR1抗体
  • 别    名: AAT5; ALK5; MSSE; SKR4; ALK-5; LDS1A; LDS2A; TGFR-1; ACVRLK4
货号: IPDX11383
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/100-1/300 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/5000-1/20000 Human,Mouse,Rat

产品详情

AliasesAAT5; ALK5; MSSE; SKR4; ALK-5; LDS1A; LDS2A; TGFR-1; ACVRLK4
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenSynthetic peptide of human TGFBR1
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下是关于TGFBR1抗体的3篇代表性文献的简要信息(文献标题和作者为假设示例,实际需根据真实文献调整):

---

1. **文献名称**: *Targeting TGFBR1 in cancer: A therapeutic antibody approach*

**作者**: Smith A et al.

**摘要**: 研究开发了一种针对TGFBR1的单克隆抗体,通过阻断TGF-β信号通路抑制肿瘤细胞的侵袭和转移。体外和体内实验表明,该抗体可显著降低多种癌症模型(如乳腺癌和结直肠癌)的肿瘤生长。

2. **文献名称**: *TGFBR1-specific antibodies attenuate fibrosis in experimental models*

**作者**: Zhang L et al.

**摘要**: 研究利用TGFBR1中和抗体抑制成纤维细胞活化,减少胶原沉积,在肺纤维化和小鼠肝纤维化模型中验证了其抗纤维化效果,提示其作为纤维化疾病治疗的潜在药物。

3. **文献名称**: *Mechanistic insights into TGFBR1 kinase inhibition by monoclonal antibodies*

**作者**: Garcia-Rendueles ME et al.

**摘要**: 通过结构生物学和功能分析,揭示了TGFBR1抗体通过结合受体激酶结构域,阻断SMAD蛋白磷酸化,从而抑制下游信号传导,为抗体药物优化提供了理论依据。

---

**注**:以上文献信息为示例性质,实际引用需检索PubMed或Web of Science等数据库获取真实文献(如搜索关键词“TGFBR1 antibody therapeutic”或“TGFBR1 inhibitor”)。真实文献可能涉及抗体开发、信号机制或临床前研究等方向。

背景信息

TGFBR1 (Transforming Growth Factor Beta Receptor 1) is a serine/threonine kinase receptor that plays a critical role in mediating signals from the TGF-β superfamily, regulating cell proliferation, differentiation, apoptosis, and immune responses. Dysregulation of TGFBR1 is implicated in various diseases, including cancer, fibrosis, and cardiovascular disorders. Antibodies targeting TGFBR1 are essential tools for studying its expression, activation, and downstream signaling pathways. These antibodies are widely used in research applications such as Western blotting, immunohistochemistry, and flow cytometry to detect receptor levels or phosphorylation status in cellular and tissue samples. Additionally, TGFBR1-targeting therapeutic antibodies or inhibitors are under investigation for diseases where TGF-β signaling is hyperactive, such as metastatic cancers or fibrotic conditions. Some studies also explore TGFBR1 mutations (e.g., in hereditary hemorrhagic telangiectasia) and its role in drug resistance. However, challenges remain in balancing therapeutic efficacy with potential side effects, given TGF-β's dual tumor-suppressive and pro-oncogenic roles. Overall, TGFBR1 antibodies serve as both research reagents and potential clinical agents, reflecting their versatility in understanding and modulating TGF-β pathway biology.

客户数据及评论

折叠内容

大包装询价

×